Finding 1092009 (2023-006)

Material Weakness Repeat Finding
Requirement
B
Questioned Costs
-
Year
2023
Accepted
2024-12-18
Audit: 333283
Organization: Unity Health Care, Inc. (MD)
Auditor: Bdo USA PC

AI Summary

  • Core Issue: The Corporation failed to provide adequate documentation for 174 fringe benefit transactions, violating 2 CFR Section 200.431.8(d).
  • Impacted Requirements: Lack of formal processes to allocate fringe benefits to specific cost objectives prevents verification of compliance with Federal funding requirements.
  • Recommended Follow-Up: Establish and implement internal controls and policies to ensure proper documentation and adherence to fringe benefits cost objectives.

Finding Text

Criteria: In accordance with 2 CFR Section 200.431.8(d), fringe benefits may be assigned to cost objectives by identifying specific benefits to specific individuals or by allocating on the basis of entity-wide salaries and wages of the employees receiving the benefits. When the allocation method is used, separate allocations must be made to selective groupings of employees, unless the non-Federal entity demonstrates that costs in relationships to salaries and wages do not differ significantly for different groups of employees. Condition: During our testing of fringe benefits expenses, we noted that all 174 sampled transactions did not have adequate supporting documentation. Charges to the Federal award for fringe benefits were based on an anticipated fringe benefit cost, for which the Corporation did not maintain an assignment of cost objectives calculation and its related requirements. Cause: The Corporation did not have formal process and policies to demonstrate adherence to the fringe benefits cost objectives of 2 CFR Section 200.431.8(d). Effect or Potential Effect: We were unable to determine whether charges to Federal awards for fringe benefits reflect specific time worked or amounts allocated to specific Federal programs, even though the charges are not in excess of amounts approved for the grant period. Questioned costs: Unknown Context: We selected 174 fringe benefit transactions charged to the Federal programs to test controls over allowable costs. Each fringe benefit transaction was calculated by applying a fringe benefit cost rate to actual salaries and wages of each employee tested. The fringe benefit cost rate was based on anticipated fringe benefit cost rate which was neither supported by an actual calculation nor analysis of the related group of employees used in such calculation. This is a condition identified per review of the Corporation’s compliance with specified requirements using a statistically valid sample. Repeat finding: This is a repeat finding from prior year. This was reported as finding 2022-006 in the 2022 report. Recommendation: We recommend the Corporation develop and incorporate internal controls and policies to demonstrate adherence to the fringe benefits cost objectives of 2 CFR Section 200.431.8(d). View of Responsible Officials: Due to turnover of several key financial executives and personnel, the Corporation did not maintain evidence of assignment of cost objectives calculations.

Categories

Allowable Costs / Cost Principles Matching / Level of Effort / Earmarking

Other Findings in this Audit

  • 515547 2023-004
    Material Weakness Repeat
  • 515548 2023-005
    Material Weakness Repeat
  • 515549 2023-006
    Material Weakness Repeat
  • 515550 2023-007
    Significant Deficiency Repeat
  • 515551 2023-004
    Material Weakness Repeat
  • 515552 2023-005
    Material Weakness Repeat
  • 515553 2023-006
    Material Weakness Repeat
  • 515554 2023-007
    Significant Deficiency Repeat
  • 515555 2023-004
    Material Weakness Repeat
  • 515556 2023-005
    Material Weakness Repeat
  • 515557 2023-006
    Material Weakness Repeat
  • 515558 2023-009
    Significant Deficiency Repeat
  • 515559 2023-004
    Material Weakness
  • 515560 2023-007
    Significant Deficiency
  • 515561 2023-004
    Material Weakness Repeat
  • 515562 2023-005
    Material Weakness Repeat
  • 515563 2023-006
    Material Weakness Repeat
  • 515564 2023-009
    Significant Deficiency Repeat
  • 515565 2023-004
    Material Weakness Repeat
  • 515566 2023-005
    Material Weakness Repeat
  • 515567 2023-006
    Material Weakness Repeat
  • 515568 2023-009
    Significant Deficiency Repeat
  • 515569 2023-004
    Material Weakness Repeat
  • 515570 2023-005
    Material Weakness Repeat
  • 515571 2023-006
    Material Weakness Repeat
  • 515572 2023-007
    Significant Deficiency Repeat
  • 515573 2023-008
    Significant Deficiency Repeat
  • 515574 2023-009
    Significant Deficiency Repeat
  • 1091989 2023-004
    Material Weakness Repeat
  • 1091990 2023-005
    Material Weakness Repeat
  • 1091991 2023-006
    Material Weakness Repeat
  • 1091992 2023-007
    Significant Deficiency Repeat
  • 1091993 2023-004
    Material Weakness Repeat
  • 1091994 2023-005
    Material Weakness Repeat
  • 1091995 2023-006
    Material Weakness Repeat
  • 1091996 2023-007
    Significant Deficiency Repeat
  • 1091997 2023-004
    Material Weakness Repeat
  • 1091998 2023-005
    Material Weakness Repeat
  • 1091999 2023-006
    Material Weakness Repeat
  • 1092000 2023-009
    Significant Deficiency Repeat
  • 1092001 2023-004
    Material Weakness
  • 1092002 2023-007
    Significant Deficiency
  • 1092003 2023-004
    Material Weakness Repeat
  • 1092004 2023-005
    Material Weakness Repeat
  • 1092005 2023-006
    Material Weakness Repeat
  • 1092006 2023-009
    Significant Deficiency Repeat
  • 1092007 2023-004
    Material Weakness Repeat
  • 1092008 2023-005
    Material Weakness Repeat
  • 1092010 2023-009
    Significant Deficiency Repeat
  • 1092011 2023-004
    Material Weakness Repeat
  • 1092012 2023-005
    Material Weakness Repeat
  • 1092013 2023-006
    Material Weakness Repeat
  • 1092014 2023-007
    Significant Deficiency Repeat
  • 1092015 2023-008
    Significant Deficiency Repeat
  • 1092016 2023-009
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
10.557 Wic Special Supplemental Nutrition Program for Women, Infants, and Children $5.29M
93.224 Community Health Centers $2.85M
93.788 Opioid Str $2.05M
93.217 Family Planning Services $1.47M
93.914 Hiv Emergency Relief Project Grants $1.34M
93.526 Fip Verification $898,419
93.527 Affordable Care Act (aca) Grants for New and Expanded Services Under the Health Center Program $862,759
93.918 Grants to Provide Outpatient Early Intervention Services with Respect to Hiv Disease $459,480
93.837 Cardiovascular Diseases Research $410,473
93.917 Hiv Care Formula Grants $409,149
93.994 Maternal and Child Health Services Block Grant to the States $328,090
93.427 Provision of Technical Assistance and Training Activities to Assure Comprehensive Cancer Control Outcomes. $113,387
93.426 The National Cardiovascular Health Program $102,468
93.898 Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations $102,041
93.855 Allergy and Infectious Diseases Research $7,112